Bayer and Regenron Agreed to Jointly Develop Treatment for Eye Disease拜耳和regenron同意共同開發治療眼科疾病
Bayer AG's Bayer Healthcare unit and Regeneron Pharmaceuticals Inc. agreed to jointly develop, and commercialize a treatment for eye disease.拜耳公司的拜耳醫藥保健股和regeneron製藥公司同意共同開發，商品化和治療眼科疾病。
The treatment, knows as VEGF Trap-Eye, blocks vascular endothelial growth factor, a protein that is responsible for blood vessel growth.治療，也知道作為血管內皮生長因子的陷阱眼座，血管內皮細胞生長因子，一種蛋白質，這是負責血管生長。 By blocking VEGF, blood vessels that contribute to eye disease are starved of much needed oxygen and nutrients.通過阻斷血管內皮生長因子，血管有助於眼科疾病是餓死的急需的氧氣和養分。
The agreement covers the world outside the United States, the companies said in a statement.協議涵蓋世界上美國以外，該公司在一份聲明中說。 Within the US, Regeneron has exclusive commercial rights and will retain 100 percent of all profits.在美國， regeneron擁有獨有的商業權利，並保留100 ％的所有利潤。
Filed under提起下 Eye Treatment眼科治療 | |
You may also like to read您也可以想讀
- Couple Forced to Choose Which One of Them Should Go Blind夫婦被迫選擇其中之一，他們應該去盲目
- Sirion Therapeutics is Ready to Develop New Treatment for Viral and Superficial Eye Infection sirion療法是準備開發新的治療病毒性心肌炎和膚淺的眼睛感染
- Melanoma, A Rare Form Of Cancer Can Be Treated With Laser Therapy黑色素瘤是一種罕見形式的癌症是可以治療與激光治療
- Syphilis Related Eye Infections are Rising Fast梅毒感染眼疾的是快速上升
- Asthma Drugs May Increase Cataract Risks in Elderly哮喘藥可能會增加白內障的風險，在老人
- Brand New Treatment For Macular Degeneration全新的治療性黃斑變性
- Indian President Dr. APJ Abdul Kalam Declares “defect-free vision for all” as National Mission; Promotes Stem Cell Research and Nano Technology印度總統博士apj卡拉姆宣布“缺陷免費為所有的遠見”作為國家的使命;促進幹細胞研究和納米技術
- Cholesterol-Lowering drug May be Good for Avoiding Cataract降膽固醇藥物可能會好，為避免白內障
- Type 2 Diabetes May Lead To Glaucoma Risk 2型糖尿病可能導致青光眼的風險
- Sickle Cell Disease Can Cause Sudden Painless Vision Loss鐮狀細胞疾病可導致突然無痛失去視覺
